Table 4 Severity of CAD/ STEMI, treatment modalities and outcome according to SES-group
G1 (n = 519) | G2 (n = 813) | G3 (n = 1554) | G4 (n = 576) | p-value | |
|---|---|---|---|---|---|
Severity of myocardial infarction | |||||
Number of coronary vesssels affected ±SD | 1.99 ± 0.8 | 1.94 ± 0.8 | 1.91 ± 0.8 | 1.84 ± 0.8 | 0.09 |
Cardiogenic shock (%) | 12.1 | 13.1 | 12.0 | 12.4 | 0.8 |
Prehospital CPR (%) | 10.9 | 11.3 | 10.8 | 10.3 | 0.5 |
Subacute MI(%) a | 19.3 | 23.9 | 20.5 | 19.9 | 0.8 |
Mean peak CK (U/l) ± SD | 1599 ± 1679 | 1838 ± 2019 | 1913 ± 2188 | 2025 ± 2167 | <0.01 |
Peak CK > 3000 U/l (%) | 13.7 | 20.5 | 20.9 | 23.3 | <0.01 |
Post AMI LVEF in % ± SD | 49.6 ± 9 | 48.9 ± 10 | 48.4 ± 11 | 47.5 ± 10 | <0.01 |
LVEF <40% (%) | 10.4 | 13.8 | 15.8 | 16.3 | 0.01 |
Treatment modalitites | |||||
Primary PCI (%) | 89.0 | 91.1 | 89.9 | 90.9 | 0.9 |
CABG (%) | 6.1 | 3.9 | 4.8 | 3.4 | 0.14 |
Conservative therapy regimen (%) | 4.8 | 4.9 | 5.2 | 5.7 | 0.8 |
Door to balloon time in min (median ± SD) | 48 ± 32 | 43 ± 44.5 | 46 ± 40 | 44 ± 41 | 0.74 |
GP2b3a-Inhibitors (%) | 70 | 67 | 66 | 70 | 0.7 |
ASA (at discharge) (%) | 94 | 96 | 94 | 95 | 0.64 |
ADP-Antagon. (ad) (%) | 90 | 90.5 | 90 | 94 | 0.23 |
Beta-blockers (ad) (%) | 83 | 84 | 80 | 84 | 0.25 |
Statins (ad) (%) | 86 | 87 | 87 | 86 | 0.9 |
ACE/ATR-Inhibitors (ad) (%) | 77 | 80 | 79 | 79 | 0.9 |
Outcome | |||||
Mortality <72 h (%) | 3.9 | 3.6 | 3.9 | 4.2 | 0.71 |
Inhospital mortality (%) | 8.8 | 7.6 | 7.9 | 8.1 | 0.71 |
1-year-mortality (%) | 15.7 | 15.1 | 14.9 | 16.3 | 0.9 |
1-year-MACCE (%) | 19.2 | 19.5 | 19.1 | 20.4 | 0.8 |
5-year-mortality (%) | 23.9 | 27.7 | 25.7 | 28.3 | 0.46 |
5-year-MACCE (%) | 30.8 | 35.7 | 36.0 | 41.1 | 0.02 |